Literature DB >> 20092246

Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast.

Kok Haw Jonathan Lim1, Premasiri Upali Telisinghe, Muhd Syafiq Abdullah, Ranjan Ramasamy.   

Abstract

Medullary carcinoma (MC) of the breast is a high grade carcinoma that has a relatively favourable prognosis compared to atypical medullary carcinoma (AMC) and other more common breast carcinomas. In a retrospective study in Brunei Darussalam of all available biopsy samples, we compared the nature of the tumour-infiltrating lymphocytes (TILs) in MC and AMC in relation to recorded tumour characteristics. CD4, CD8, CD20, CD25, CD45RO, and CD56 and common tumour biomarkers were detected immunohistochemically. The 11 cases of MC had no nodal metastases and survived without relapse, suggesting good tumour control. In contrast, 7 cases of nodal metastases and 1 relapse were observed in 12 AMCs. Although not statistically significant, there was a tendency for a greater proportion of AMCs to express the Her2/neu oncogene. Higher proportions of CD45RO+ and CD8+ cells, and lower levels of CD20+ cells, were characteristic of TILs in MC compared to AMC. The ratio of CTL to B-lineage cells in TILs in both tumours considered together was inversely related to the expression of HER2/neu and the presence of nodal metastases. The findings suggest that CTLs, rather than antibodies, may give better tumour control in MC relative to AMC. We propose that a comparison of the cellular, molecular and immunological characteristics of MC and AMC, as a paired model system, in a multi-centre investigation with a much larger number of samples will be valuable for better understanding mechanisms of tumour immunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20092246      PMCID: PMC2964018     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  16 in total

1.  Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes.

Authors:  Beatrix Kotlan; Peter Simsa; Jean-Luc Teillaud; Wolf Herman Fridman; Jozsef Toth; Michael McKnight; Mark C Glassy
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

Review 2.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

3.  Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast.

Authors:  E Yakirevich; O B Izhak; G Rennert; Z G Kovacs; M B Resnick
Journal:  Mod Pathol       Date:  1999-11       Impact factor: 7.842

4.  The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

Authors: 
Journal:  Oncologist       Date:  1998

5.  Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer.

Authors:  J A Coronella; P Telleman; G A Kingsbury; T D Truong; S Hays; R P Junghans
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

6.  Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast.

Authors:  Hajime Kuroda; Jun-ichi Tamaru; Goi Sakamoto; Kiyoshi Ohnisi; Shinji Itoyama
Journal:  Virchows Arch       Date:  2004-11-30       Impact factor: 4.064

7.  Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype.

Authors:  L Orlando; G Renne; A Rocca; G Curigliano; M Colleoni; G Severi; G Peruzzotti; S Cinieri; G Viale; G Sanna; A Goldhirsch
Journal:  Ann Oncol       Date:  2005-04-26       Impact factor: 32.976

8.  Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast.

Authors:  D Tamiolakis; C Simopoulos; A Cheva; M Lambropoulou; A Kotini; T Jivannakis; N Papadopoulos
Journal:  Eur J Gynaecol Oncol       Date:  2002       Impact factor: 0.196

9.  Cancer vaccines: an overview.

Authors:  Lloyd J Old
Journal:  Cancer Immun       Date:  2008-03-12

10.  Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma.

Authors:  V Rapin; G Contesso; H Mouriesse; F Bertin; M J Lacombe; J D Piekarski; J P Travagli; C Gadenne; S Friedman
Journal:  Cancer       Date:  1988-06-15       Impact factor: 6.860

View more
  10 in total

Review 1.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Authors:  Laura Annaratone; Eliano Cascardi; Elena Vissio; Ivana Sarotto; Ewa Chmielik; Anna Sapino; Enrico Berrino; Caterina Marchiò
Journal:  Pathobiology       Date:  2020-04-23       Impact factor: 4.342

2.  Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.

Authors:  Lutfiye Demir; Seyran Yigit; Hulya Ellidokuz; Cigdem Erten; Isil Somali; Yuksel Kucukzeybek; Ahmet Alacacioglu; Suna Cokmert; Alper Can; Murat Akyol; Ahmet Dirican; Vedat Bayoglu; Aysegul Akder Sari; Mustafa Oktay Tarhan
Journal:  Clin Exp Metastasis       Date:  2013-07-09       Impact factor: 5.150

3.  High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors.

Authors:  Niklas K Finnberg; Lori S Hart; Nathan G Dolloff; Zachary B Rodgers; David T Dicker; Wafik S El-Deiry
Journal:  Am J Pathol       Date:  2011-10-03       Impact factor: 4.307

Review 4.  Influence of human immune cells on cancer: studies at the University of Colorado.

Authors:  Tullia C Bruno; Jena D French; Kimberly R Jordan; Oscar Ramirez; Trisha R Sippel; Virginia F Borges; Bryan R Haugen; Martin D McCarter; Allen Waziri; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

5.  Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.

Authors:  Raoul Droeser; Inti Zlobec; Ergin Kilic; Uwe Güth; Michael Heberer; Giulio Spagnoli; Daniel Oertli; Coya Tapia
Journal:  BMC Cancer       Date:  2012-04-03       Impact factor: 4.430

Review 6.  The impact of the immune system on tumor: angiogenesis and vascular remodeling.

Authors:  Christian Stockmann; Dirk Schadendorf; Ralph Klose; Iris Helfrich
Journal:  Front Oncol       Date:  2014-04-08       Impact factor: 6.244

Review 7.  High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers.

Authors:  Jung-Hyun Rho; Paul D Lampe
Journal:  Proteomes       Date:  2014-01-13

8.  Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment.

Authors:  María José Godoy-Calderón; Eglys González-Marcano; Jeismar Carballo; Ana Federica Convit
Journal:  Oncotarget       Date:  2019-11-12

9.  B cells promote tumor progression via STAT3 regulated-angiogenesis.

Authors:  Chunmei Yang; Heehyoung Lee; Sumanta Pal; Veronica Jove; Jiehui Deng; Wang Zhang; Dave S B Hoon; Mark Wakabayashi; Stephen Forman; Hua Yu
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

10.  Autologous tumor cells/bacillus Calmette-Guérin/formalin-based novel breast cancer vaccine induces an immune antitumor response.

Authors:  María José Godoy-Calderón; Víctor Salazar; Eglys González-Marcano; Ana Federica Convit
Journal:  Oncotarget       Date:  2018-04-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.